JO3762B1 - حبيبات للمستحضرات الدوائية وطرق أجهزة لإنتاجها - Google Patents

حبيبات للمستحضرات الدوائية وطرق أجهزة لإنتاجها

Info

Publication number
JO3762B1
JO3762B1 JOP/2010/0446A JOP20100446A JO3762B1 JO 3762 B1 JO3762 B1 JO 3762B1 JO P20100446 A JOP20100446 A JO P20100446A JO 3762 B1 JO3762 B1 JO 3762B1
Authority
JO
Jordan
Prior art keywords
granules
pharmaceutical preparations
preparations
methods
improved
Prior art date
Application number
JOP/2010/0446A
Other languages
English (en)
Inventor
Casper Larsen Crilles
Wittendorff Jorgen
Hansen Tue
Manby Pedersen Kenneth
NISSEN Birgitte
Poulsen Helle
Hoeg-Moller Carsten
Original Assignee
Ferring Int Center Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42110308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3762(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Int Center Sa filed Critical Ferring Int Center Sa
Application granted granted Critical
Publication of JO3762B1 publication Critical patent/JO3762B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/609—Amides, e.g. salicylamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ما يتم الكشف عنه هو مستحضرات دوائية حبيبية محسنة، معا مع طرق محسنة واستخدام جهاز لتحضير الحبيبات. تعتبر هذه الطرق مفيدة تحديدا لعمل المستحضرات الدوائية للجرعات الصلبة التي تعطى عن طريق الفم، وتعتبر مناسبة تحديدا لإنتاج الحبيبات التي تحتوي على حمض 5-أمينو ساليسيليك (5-ASA) لمعالجة مرض التهاب الأمعاء. تعرض الحبيبات توزيع طول أكثر تحديدا، وبالتالي توزيع نسبة مظهر، وتمتلك نتيجة لذلك جانب حل أكبر بعد المزيد من المعالجة.
JOP/2010/0446A 2009-12-18 2010-12-15 حبيبات للمستحضرات الدوائية وطرق أجهزة لإنتاجها JO3762B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09179877A EP2340812A1 (en) 2009-12-18 2009-12-18 Granules for pharmaceutical preparations, methods and apparatus for their production

Publications (1)

Publication Number Publication Date
JO3762B1 true JO3762B1 (ar) 2021-01-31

Family

ID=42110308

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2010/0446A JO3762B1 (ar) 2009-12-18 2010-12-15 حبيبات للمستحضرات الدوائية وطرق أجهزة لإنتاجها

Country Status (28)

Country Link
US (2) US8765185B2 (ar)
EP (2) EP2340812A1 (ar)
JP (1) JP5593396B2 (ar)
KR (1) KR101882880B1 (ar)
CN (2) CN102791257B (ar)
AR (1) AR079536A1 (ar)
AU (1) AU2010332884B2 (ar)
BR (1) BR112012014935B1 (ar)
CA (1) CA2784235C (ar)
DK (1) DK2512453T4 (ar)
ES (1) ES2612870T5 (ar)
FI (1) FI2512453T4 (ar)
HR (1) HRP20161639T4 (ar)
HU (1) HUE031228T2 (ar)
IL (1) IL220319A (ar)
JO (1) JO3762B1 (ar)
LT (1) LT2512453T (ar)
MX (2) MX351365B (ar)
NL (1) NL1038373C2 (ar)
NZ (1) NZ600582A (ar)
PL (1) PL2512453T5 (ar)
PT (1) PT2512453T (ar)
RS (1) RS55438B2 (ar)
RU (1) RU2584349C2 (ar)
SI (1) SI2512453T2 (ar)
TW (1) TWI511723B (ar)
WO (1) WO2011073245A2 (ar)
ZA (1) ZA201204441B (ar)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2520197A1 (en) * 2003-04-23 2004-11-04 Ferring B.V. Sachet for a pharmaceutical composition
HUE048293T2 (hu) 2008-10-02 2020-07-28 Salix Pharmaceuticals Ltd Eljárások hepatikus enkefalopátia kezelésére
EP2340812A1 (en) 2009-12-18 2011-07-06 Ferring International Center S.A. Granules for pharmaceutical preparations, methods and apparatus for their production
US20140141075A1 (en) 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
DE202017102645U1 (de) * 2017-05-03 2018-08-06 Romaco Kilian Gmbh Ablaufvorrichtung für Presslinge einer Rundläufer-Tablettenpresse sowie Rundläufer-Tablettenpresse mit Ablaufvorrichtung
RU2667637C1 (ru) * 2017-06-26 2018-09-21 Гермес Арцнаймиттель ГмбХ Фармацевтическая композиция для перорального применения, содержащая n-ацетилцистеин с маскированным вкусом
ES2938609T3 (es) 2017-09-20 2023-04-13 Tillotts Pharma Ag Preparación de formas farmacéuticas sólidas que comprenden anticuerpos mediante estratificación de solución/suspensión
EP3459529A1 (en) 2017-09-20 2019-03-27 Tillotts Pharma Ag Preparation of sustained release solid dosage forms comprising antibodies by spray drying
ES2938608T3 (es) 2017-09-20 2023-04-13 Tillotts Pharma Ag Método para preparar una forma farmacéutica sólida que comprende anticuerpos mediante granulación en húmedo, extrusión y esferonización
KR102161235B1 (ko) * 2020-07-22 2020-09-29 주식회사 피티케이 이송 일체형 과립 제조 장치 및 방법
CN116033892A (zh) * 2020-08-18 2023-04-28 悠哈味觉糖有限公司 口中速崩性固体食品及其制造方法
CN114472139A (zh) * 2022-01-04 2022-05-13 安徽宏信药业发展有限公司 一种中药药丸干燥筛选装置
CN115445902B (zh) * 2022-09-21 2023-06-06 重庆科技学院 一种条形颗粒物三维尺寸分选方法及装置
AU2024241638A1 (en) 2023-03-28 2025-10-09 Tillotts Pharma Ag Solid oral dosage form comprising antibodies for sustained release in the lower gastrointestinal tract
CN116942532B (zh) * 2023-09-20 2023-12-12 北京爱力佳医药科技有限公司 一种粉状药物制备装置

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57500432A (ar) 1980-03-20 1982-03-11
DE3786544T2 (de) * 1986-03-10 1994-02-03 Cri Int Inc Verfahren zur Sortierung und Isolierung von Katalysator-Formteilchen nach ihrer Länge.
US4720473A (en) * 1986-03-10 1988-01-19 Cri International, Inc. Production of improved catalyst-type particles using length and density grading
JPH0827133B2 (ja) 1993-07-13 1996-03-21 不二パウダル株式会社 湿潤粉粒体の処理装置
US6004581A (en) * 1995-12-21 1999-12-21 Farmaceutisk Laboratorium Ferring A/S Modified release oral pharmaceutical composition and method for the treatment of bowel diseases
BR9612213A (pt) 1995-12-21 1999-12-28 Ferring Farma Lab Composição farmaceutica oralmente liberada modificada contendo 5-asa e método para o tratamento de doenças do instetino.
AUPO637197A0 (en) 1997-04-23 1997-05-15 F.H. Faulding & Co. Limited Taste-masked pharmaceutical compositions
DE19724181A1 (de) * 1997-06-09 1998-12-10 Bayer Ag Multiple-unit-retard-Zubereitungen und Verfahren zu ihrer Herstellung
JP2000128774A (ja) 1998-10-26 2000-05-09 Tanabe Seiyaku Co Ltd 薬物を含有する球形微粒子の製法
US6146685A (en) 1998-11-05 2000-11-14 Delsys Pharmaceutical Corporation Method of deposition a dry powder and dispensing device
US6962717B1 (en) * 1999-01-29 2005-11-08 Disphar International B.V. Pharmaceutical compositions
US6735487B1 (en) 1999-07-01 2004-05-11 Ods Properties, Inc. Interactive wagering system with promotions
GB0113841D0 (en) * 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
AR036797A1 (es) 2001-10-15 2004-10-06 Ferring Bv Un metodo para preparar una composicion farmaceutica que comprende acido 5-aminosalicilico para utilizar en el tratamiento de colitis ulcerosa y enfermedades de crohn
PT1441700E (pt) * 2001-10-15 2007-10-29 Ferring Bv Método para a preparação de uma composição compreendendo ácido 5-aminosalicílico para uso em tratamento de colites ulcerosas ou da doença de crohn
US7445796B2 (en) 2002-08-19 2008-11-04 L. Perrigo Company Pharmaceutically active particles of a monomodal particle size distribution and method
CA2520197A1 (en) 2003-04-23 2004-11-04 Ferring B.V. Sachet for a pharmaceutical composition
EP1470819A1 (en) * 2003-04-23 2004-10-27 Ferring B.V. High drug load mesalazine sachet
EP1547601A1 (en) 2003-12-23 2005-06-29 Ferring B.V. Coating method
US7207505B2 (en) 2004-06-04 2007-04-24 Bender Martin P Method for producing small granules
DE102004028977A1 (de) * 2004-06-16 2006-01-05 Add Advanced Drug Delivery Technologies Ltd. Neutralpellets
CA2630037C (en) 2005-11-17 2015-03-31 Teva Pharmaceutical Industries Ltd. Methods for isolating propargylated aminoindans
EP2340812A1 (en) 2009-12-18 2011-07-06 Ferring International Center S.A. Granules for pharmaceutical preparations, methods and apparatus for their production

Also Published As

Publication number Publication date
ES2612870T3 (es) 2017-05-19
CN102791257A (zh) 2012-11-21
FI2512453T9 (fi) 2025-06-13
HRP20161639T4 (hr) 2025-06-20
HUE031228T2 (en) 2017-07-28
HRP20161639T1 (hr) 2017-02-10
EP2512453A2 (en) 2012-10-24
SI2512453T1 (sl) 2017-02-28
CA2784235C (en) 2019-01-15
MX2012006851A (es) 2012-08-31
WO2011073245A3 (en) 2011-08-11
PL2512453T3 (pl) 2017-03-31
CN102791257B (zh) 2017-03-01
RS55438B2 (sr) 2025-06-30
AU2010332884B2 (en) 2015-12-10
NZ600582A (en) 2014-09-26
CA2784235A1 (en) 2011-06-23
CN105769772A (zh) 2016-07-20
MX351365B (es) 2017-10-12
PL2512453T5 (pl) 2025-07-07
ZA201204441B (en) 2013-02-27
TW201125556A (en) 2011-08-01
US20130022681A1 (en) 2013-01-24
FI2512453T4 (fi) 2025-05-23
JP5593396B2 (ja) 2014-09-24
BR112012014935A2 (pt) 2016-03-08
RS55438B1 (sr) 2017-04-28
EP2340812A1 (en) 2011-07-06
DK2512453T3 (en) 2017-01-09
EP2512453B2 (en) 2025-03-12
KR20120102775A (ko) 2012-09-18
RU2584349C2 (ru) 2016-05-20
AR079536A1 (es) 2012-02-01
IL220319A (en) 2016-03-31
US8765185B2 (en) 2014-07-01
IL220319A0 (en) 2012-08-30
AU2010332884A1 (en) 2012-07-05
EP2512453B1 (en) 2016-11-09
LT2512453T (lt) 2016-12-27
BR112012014935B1 (pt) 2021-12-21
TWI511723B (zh) 2015-12-11
ES2612870T5 (en) 2025-05-09
SI2512453T2 (sl) 2025-06-30
WO2011073245A2 (en) 2011-06-23
US9114083B2 (en) 2015-08-25
JP2013514312A (ja) 2013-04-25
PT2512453T (pt) 2016-12-16
NL1038373C2 (en) 2011-06-21
US20140328934A1 (en) 2014-11-06
KR101882880B1 (ko) 2018-07-27
RU2012124834A (ru) 2014-01-27
DK2512453T4 (da) 2025-06-02

Similar Documents

Publication Publication Date Title
JO3762B1 (ar) حبيبات للمستحضرات الدوائية وطرق أجهزة لإنتاجها
IL274602A (en) Pharmaceutical tablets containing eltrombopag olamine, methods for their preparation and use thereof in the preparation of medicaments for treating thrombocytopenia
MY178082A (en) Solid pharmaceutical compositions and processes for their production
IL222120A (en) Annals (indole-1-yl) -carbonylalkyl, process for preparation, pharmaceutical preparations containing them and their use in the preparation of cancer drugs
IL195294A (en) A process for the manufacture of high purity spinamide or relapinamide, their use in the preparation of medicaments and medicinal preparations containing them
NZ592325A (en) Extended release oral acetaminophen/tramadol dosage form
MY171929A (en) Corticosteroids for the treatment of joint pain
IL204887A (en) Acetamide History, Pharmaceuticals Containing Them, Methods of Preparing and Using It in the Preparation of Diabetes Medications
IL198314A (en) History of Quinuclidine of (hetero) Acrylic Cyclohepethecarboxylic Acid, Process of Preparation, Medicinal Preparations Containing Them and Use of Drug Preparation for Treatment
IL218598A (en) Oral solid dosage form containing nanoparticles and process for preparation using gelatin from fish
IL203936A (en) HISTORY 4 - Pyrimidinsulfamide, Process for Preparation, Pharmaceutical Preparations Containing and Using it for Medication Preparation
SG196810A1 (en) Controlled release pharmaceutical or foodformulation and process for its preparation
FR2937972B1 (fr) Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
EA201490653A1 (ru) Производные эстра-1,3,5(10),16-тетраен-3-карбоксамида, способ их получения, содержащие их фармацевтические препараты, а также их применение для получения лекарственных средств
IL195931A0 (en) Pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine and methods for its production
TN2010000135A1 (en) Galenical formulations of organic compounds
WO2008146016A3 (en) Cyclodextrins for administering fatty acids in tablets
PH12015500823A1 (en) Modified release formulations for oprozomib
DE602008006243D1 (de) Pharmazeutische kombination aus aliskiren und valsartan
IL213671A (en) Pharmaceutical preparations containing alglitazar, a process for their preparation and use for the preparation of medicines
MY139086A (en) Use of debranched starch in extrusion-spheronization pharmaceutical pellets
MY149863A (en) Delayed-release glucocorticoid treatment of rheumatoid disease
NZ707033A (en) Dispersible nimorazole tablet
Karen et al. Development and evaluation of floating drug delivery system of itopride hydrochloride
Shchykovskyi et al. Importance of study influence excipients and process parameters on quality characteristic drugs